NZ Hepatitis Research Review Issue 31

In this issue:

Sofosbuvir + NS5A inhibitor for recurrent HCV infection post-LT
Extrahepatic cancer risk linked to HCV or HBV cirrhosis
High rates of occult HCV infection after DAAs
Besifovir dipivoxil maleate shows efficacy in chronic HBV
Too few ‘grey zone’ patients proceed to liver biopsy
Eliminating HCV as a public health threat in Australia
The global burden of HDV infection
Glecaprevir/pibrentasvir in chronic HCV genotype 3 infection
Data on viral hepatitis in a gang population
Simplified point-of-care testing for HCV infection

Please login below to download this issue (PDF)